After Former Citron Short Target AveXis Gets Bought, Analyst Asks 'who's Next'
Monday, April 9, 2018 11:25 AM EDT
AveXis shares are surging after the gene therapy researcher announced an agreement to be acquired by Novartis for $218 per share, or $8.7billion in cash. This comes two years after Citron Research made a short call of a AveXis $5 price target.